Filtra Consult. (539098)

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• ROCE of 16.53% suggests decent capital efficiency
• Sales growth of 9.26% shows modest business expansion
• Dividend yield of 3.03% provides some income support
• Trading near 52-week high indicates current market confidence

Concerns

• Profit growth negative at -6.25% while P/E is expensive at 26.12
• Piotroski F-Score of 4/9 points to weak fundamental health
• PEG of 2.82 implies valuation is far ahead of growth
• Insufficient data on book value, debt, ROE, and promoter holding prevents proper margin-of-safety analysis

AI Analysis

At first glance, Filtra Consult appears to be a steady, small-cap utility with a respectable ROCE of 16.53% and a dividend yield of 3.03%. But as Graham would say, numbers must be read with suspicion, not hope. Sales grew 9.26%, yet profits actually fell 6.25%. That is a red flag: the company is getting bigger but not more profitable. At a P/E of 26.12, the market is paying a rich price for a business whose earnings are contracting. The PEG ratio of 2.82 tells me growth is nowhere near justifying this valuation. The Piotroski F-Score of only 4/9 reinforces my caution — the financial health is mediocre, with multiple warning signs beneath the surface. I also cannot calculate book value, ROE, or debt-equity because the data is simply not disclosed. That is unacceptable for a disciplined investor. If I cannot assess the balance sheet, I cannot estimate intrinsic value, and without intrinsic value there is no margin of safety. The stock trades near its 52-week high of ₹98.40, up from ₹46.95, so Mr. Market is enthusiastic. But enthusiasm is not evidence. The latest quarter shows sales of ₹47 Cr and net profit of just ₹2 Cr — a thin margin that leaves little room for error. The dividend offers some comfort, but a 3.03% yield cannot compensate for deteriorating earnings and an inflated multiple. This looks like a slow grower at a fast-grower price. I would keep it on the watchlist, not in the portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer